← Back to Search

Virus Therapy

VBI-2902a for Coronavirus

Phase 1
Waitlist Available
Led By Joanne M Langley, MD
Research Sponsored by VBI Vaccines Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 1 year
Awards & highlights

Study Summary

This trial is testing two potential COVID-19 vaccines. One is for the original strain of the virus, and one is for a new strain. The trial is testing different doses and whether or not the vaccine is effective.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, approximately 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse events leading to discontinuation of study vaccination
Adverse events leading to study discontinuation
Rate and severity of local and systemic solicited adverse events after each study vaccination
+3 more
Secondary outcome measures
GMT and the geometric mean fold increase in serum antibody titer post-vaccination over baseline
Geometric Mean Titer (GMT) and the geometric mean fold increase in serum antibody titer post-vaccination over baseline
Rate and severity of laboratory abnormalities (hematology, biochemistry, urinalysis)
+3 more

Trial Design

5Treatment groups
Experimental Treatment
Placebo Group
Group I: Phase 1b, Group G4Experimental Treatment1 Intervention
27 participants age 18-54 will receive VBI-2905a at a dose of 5 μg of S protein at Day 1
Group II: Phase 1a, Group G2Experimental Treatment1 Intervention
20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Days 1 and 28
Group III: Phase 1a, Group G1Experimental Treatment2 Interventions
20 participants age 18-54 will receive VBI-2902a at a dose of 5 μg of S protein at Day 1 and placebo at Day 28
Group IV: Phase 1a, Group G3Placebo Group1 Intervention
20 participants age 18-54 will receive placebo at Days 1 and 28
Group V: Phase 1b, Group G5Placebo Group1 Intervention
27 participants age 18-54 will receive placebo at Day 1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VBI-2902a
2021
Completed Phase 1
~120
Placebo
1995
Completed Phase 3
~2670
VBI-2905a
2021
Completed Phase 1
~120

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

VBI Vaccines Inc.Lead Sponsor
11 Previous Clinical Trials
5,578 Total Patients Enrolled
Joanne M Langley, MDPrincipal InvestigatorCanadian Center for Vaccinology
4 Previous Clinical Trials
1,784 Total Patients Enrolled
William Cameron, MDPrincipal InvestigatorOttawa Hospital
3 Previous Clinical Trials
215 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
2021. "Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04773665.
~28 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top